Research programme: angiopoietin modulators - Regeneron

Drug Profile

Research programme: angiopoietin modulators - Regeneron

Alternative Names: Angiopoeitin-like 4 antibody - Regeneron; ANGPTL4 - Regeneron

Latest Information Update: 11 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; University of California at San Francisco
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inducing agents; Angiogenesis inhibitors; Angiopoietin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; Inflammation; Metabolic disorders

Most Recent Events

  • 02 Mar 2016 Preclinical trials in Metabolic disorders in USA (unspecified route)
  • 02 Mar 2011 Preclinical development is ongoing in USA
  • 19 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top